Results 151 to 160 of about 23,073,058 (182)

Pharmaco-economic profile, effectiveness, and safety of a dolutegravir based first line ART regimen among people living with HIV in South Gujarat. [PDF]

Indian J Med Res
Sojitra B, Patel C, Bhatt KN, Pandya S, Shah P, Shah A, Patel J, Adwani C, Panchal V.   +8 more
europepmc   +1 more source

Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list system. [PDF]

Cost Eff Resour Alloc
Kim HJ, Nam KA, Jang SC, Ban KA, Lee EK, Park SK.   +5 more
europepmc   +1 more source

Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system. [PDF]

Front Pharmacol
Zhai F, Li H, Jiang C, Mao J, Chen J, You C.   +5 more
europepmc   +1 more source

Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data. [PDF]

Hematol Rep
Messori A, Gasperoni L, Del Bono L, Damuzzo V.   +3 more
europepmc   +1 more source

Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-Resistant <i>Acinetobacter baumannii</i> with Diverse <i>β</i>-Lactamase Profiles: A Multicenter Study in China. [PDF]

Infect Drug Resist
Liu C, Chen Y, Wang L, Wang J, Xu D, Chen Z, Shu C, He Y.   +7 more
europepmc   +1 more source

Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis. [PDF]

PLoS One
Chen Q, Chen T, Lin W, Chen X.
europepmc   +1 more source

Low compliance and polypharmacy as key negative predictors in highly effective anti-psoriatic treatments. [PDF]

J Eur Acad Dermatol Venereol
Damiani G.
europepmc   +1 more source

Economic evaluation of liraglutide versus sitagliptin in the treatment of type 2 diabetes mellitus inadequately controlled with metformin. [PDF]

Front Clin Diabetes Healthc
Yang F, Zheng X, Li W, Zhao Z.
europepmc   +1 more source